U.S. Markets close in 2 hrs 22 mins
  • S&P 500

    3,703.18
    +55.89 (+1.53%)
     
  • Dow 30

    29,588.91
    +453.92 (+1.56%)
     
  • Nasdaq

    10,978.06
    +148.56 (+1.37%)
     
  • Russell 2000

    1,710.05
    +47.54 (+2.86%)
     
  • Crude Oil

    81.30
    +2.80 (+3.57%)
     
  • Gold

    1,669.50
    +33.30 (+2.04%)
     
  • Silver

    18.86
    +0.53 (+2.88%)
     
  • EUR/USD

    0.9744
    +0.0146 (+1.5200%)
     
  • 10-Yr Bond

    3.7310
    -0.2330 (-5.88%)
     
  • Vix

    31.01
    -1.59 (-4.88%)
     
  • GBP/USD

    1.0897
    +0.0166 (+1.5430%)
     
  • USD/JPY

    144.0020
    -0.7890 (-0.5449%)
     
  • BTC-USD

    19,578.55
    +572.07 (+3.01%)
     
  • CMC Crypto 200

    446.16
    +17.38 (+4.05%)
     
  • FTSE 100

    7,005.39
    +20.80 (+0.30%)
     
  • Nikkei 225

    26,173.98
    -397.89 (-1.50%)
     

What Type Of Shareholders Own The Most Number of Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?

·4 min read

The big shareholder groups in Viking Therapeutics, Inc. (NASDAQ:VKTX) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. Companies that used to be publicly owned tend to have lower insider ownership.

With a market capitalization of US$269m, Viking Therapeutics is a small cap stock, so it might not be well known by many institutional investors. Our analysis of the ownership of the company, below, shows that institutions are noticeable on the share registry. Let's delve deeper into each type of owner, to discover more about Viking Therapeutics.

See our latest analysis for Viking Therapeutics

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Viking Therapeutics?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

Viking Therapeutics already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Viking Therapeutics' earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
earnings-and-revenue-growth

It would appear that 9.0% of Viking Therapeutics shares are controlled by hedge funds. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. ArrowMark Colorado Holdings, LLC is currently the company's largest shareholder with 9.0% of shares outstanding. In comparison, the second and third largest shareholders hold about 9.0% and 6.5% of the stock. Furthermore, CEO Brian Lian is the owner of 2.1% of the company's shares.

Looking at the shareholder registry, we can see that 50% of the ownership is controlled by the top 22 shareholders, meaning that no single shareholder has a majority interest in the ownership.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of Viking Therapeutics

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

We can see that insiders own shares in Viking Therapeutics, Inc.. It has a market capitalization of just US$269m, and insiders have US$7.1m worth of shares, in their own names. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying.

General Public Ownership

The general public-- including retail investors -- own 41% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Public Company Ownership

We can see that public companies hold 9.0% of the Viking Therapeutics shares on issue. It's hard to say for sure but this suggests they have entwined business interests. This might be a strategic stake, so it's worth watching this space for changes in ownership.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. To that end, you should learn about the 5 warning signs we've spotted with Viking Therapeutics (including 2 which are potentially serious) .

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.